Curative Biotechnology Inc

Curative Biotechnology, Inc. is a development-stage biopharmaceutical company founded in 1995 and focused on identifying, in-licensing, and developing disease-modifying therapeutic drug candidates for rare disease indications and unmet medical needs. The company operates across three therapeutic areas: degenerative eye disease, infectious disease, and neuro-oncology, with primary strategic focus on its ophthalmology/degenerative eye disease platform. The company is pursuing novel therapies including a reformulated metformin eye drop for age-related macular degeneration under collaboration with the National Eye Institute, an immunotherapy for advanced rabies with orphan drug designation, and a monoclonal antibody therapeutic for neuro-oncology applications. Curative Biotechnology seeks to accelerate the development timeline for rare disease therapies through strategic partnerships and licensing agreements with academic institutions and biotech partners.